胸腺肽α_(1)治疗AECOPD合并肺炎的效果及对患者炎症因子、免疫功能的影响

Therapeutic Effect of Thymosin α in Patients with AECOPD Complicated with Pneumonia and Its Influence on Inflammatory Factors and Immune Function

目的:探讨胸腺肽α_(1)治疗慢性阻塞性肺疾病急性加重期(AECOPD)合并肺炎的效果及对患者炎症因子、免疫功能的影响。方法:回顾性分析2019年7月-2020年10月本院接诊的90例AECOPD合并肺炎患者临床资料。按照治疗方式分为观察组和对照组,每组45例。对照组采用常规治疗,观察组联合应用注射用胸腺肽α_(1)治疗。比较两组临床疗效和治疗前后动脉血氧分压(PaO2)、动脉二氧化碳分压(PaCO2)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、IL-8、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平,并记录不良反应发生率。结果:观察组治疗总有效率为91.11%,明显高于对照组的73.33%,差异有统计学意义(P<0.05);治疗后,观察组PaO2水平明显高于对照组,PaCO2水平明显低于对照组,差异均有统计学意义(P<0.05);观察组血清TNF-α、IL-6、IL-8水平均明显低于对照组,差异均有统计学意义(P<0.05);观察组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平均明显高于对照组,差异有统计学意义(P<0.05);两组不良反应总发生率为11.11%和6.67%,差异无统计学意义(P>0.05)。结论:胸腺肽α_(1)治疗AECOPD合并肺炎患者效果明显,可有效改善血清炎症因子、免疫功能水平的表达,值得推广应用。

Objective:To investigate the therapeutic effect of thymosin α_(1) in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) complicated with pneumonia and its effect on the immune function of inflammatory cytokines.Method:The clinical data of 90 patients with AECOPD complicated with pneumonia in our hospital from July 2019 to October 2020 were retrospectively analyzed.According to treatment methods,they were divided into the observation group and the control group,45 cases in each group.The control group was received conventional treatment,and the observation group was combined with thymosin α_(1) injection.The clinical efficacy,the arterial partial pressure of oxygen (PaO2),arterial partial pressure of carbon dioxide (PaCO2),tumor necrosis factor-α (TNF-α),interleukin-6 (IL-6),IL-8,CD3^(+),CD4^(+),CD4^(+)/CD8^(+) levels before and after treatment between two groups were compared,and the incidence of adverse reactions was recorded.Result:The total effective rate of clinical efficacy in the observation group was 91.11%,which was significantly higher than 73.33% of the control group,the difference was statistically significant (P<0.05).After treatment,the PaO2 level of the observation group was significantly higher than that of the control group,the PaCO2 level of the observation group was significantly lower than that of the control group,the differences were statistically significant (P<0.05);the levels of serum TNF-α,IL-6 and IL-8 in the observation group were significantly lower than those in the control group,and the differences were statistically significant (P<0.05);the CD3^(+),CD4^(+),CD4^(+)/CD8^(+) levels of the observation group were significantly higher than those of the control group,and the differences were statistically significant (P<0.05).The total incidence of adverse reactions in the two groups was 11.11% and 6.67%,the difference was not statistically significant (P>0.05).Conclusion:Thymosin α_(1) is effective in the treatment of AECOPD patients with pneumonia,which can effectively improve the expression of serum inflammatory factors and immune function,and is worthy of promotion and application.